Compare VSME & PHGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VSME | PHGE |
|---|---|---|
| Founded | 2013 | 2015 |
| Country | Hong Kong | Israel |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.6M | 6.9M |
| IPO Year | 2023 | N/A |
| Metric | VSME | PHGE |
|---|---|---|
| Price | $0.08 | $2.03 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $26.00 |
| AVG Volume (30 Days) | ★ 11.3M | 131.6K |
| Earning Date | 04-14-2026 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $7,483,152.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.07 | $1.50 |
| 52 Week High | $3.21 | $22.06 |
| Indicator | VSME | PHGE |
|---|---|---|
| Relative Strength Index (RSI) | 25.16 | 47.63 |
| Support Level | $0.07 | $1.50 |
| Resistance Level | $0.12 | $2.35 |
| Average True Range (ATR) | 0.01 | 0.49 |
| MACD | 0.03 | -0.19 |
| Stochastic Oscillator | 16.52 | 11.03 |
VS Media Holdings Ltd manages a network of digital Creators who create and publish content to social media platforms such as YouTube, Facebook, Instagram, and TikTok. Its Creators include influencers, KOLs-Key Opinion Leaders, bloggers, and other content creators who cultivate fan bases on social media platforms. The company's business provides value to two business stakeholders: Creators and Brands. The Value to Creators, that empowers and supports Creators by providing them with production facilities, training, and funding to produce quality content and the Value to Brands, where the company bridges the divide between Brands and Creators by helping Brands reach their target audience effectively by advising on content and budget and recommending specific Creators.
BiomX Inc is engaged in developing both natural and engineered phage cocktails and personalized treatments designed to target and destroy harmful bacteria in chronic diseases, including cystic fibrosis and diabetic foot osteomyelitis. It discovers and validates proprietary bacterial targets and customizes phage compositions against these targets, and applies its BOLT (BacteriOphage Lead to Treatment) platform to customize phage compositions against these targets. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF. Its BX211 - Treatment of Diabetic Foot Osteomyelitis (DFO).